This page is part of the Potential Drug-Drug Interaction (PDDI) Clinical Decision Support (CDS) (FHIR IG) (v0.1.0: STU 1 Ballot 1) based on FHIR (HL7® FHIR® Standard) v3.5.0. No current official version has been published yet. For a full list of available versions, see the Directory of published versions

valueset-rimexolone-exclude

<ValueSet xmlns="http://hl7.org/fhir">
  <id value="valueset-rimexolone-exclude"/>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><h2>Exclude Rimexolone Medications Value Set</h2><div><p>ValueSet containing drug identifiers to exclude. Criteria is explicitly stating topical, gel, cream, ointment, otic, or ophthalmic formulations.</p>
</div><p><b>Copyright Statement:</b> Attribution CC BY</p><p>This value set includes codes from the following code systems:</p><ul><li>Include these codes as defined in <a href="http://www.nlm.nih.gov/research/umls/rxnorm"><code>http://www.nlm.nih.gov/research/umls/rxnorm</code></a><table class="none"><tr><td style="white-space:nowrap"><b>Code</b></td><td><b>Display</b></td></tr><tr><td>207446</td><td>rimexolone 10 MG/ML Ophthalmic Suspension [Vexol]</td><td/></tr><tr><td>365826</td><td>rimexolone Ophthalmic Suspension [Vexol]</td><td/></tr><tr><td>199115</td><td>rimexolone 10 MG/ML Ophthalmic Suspension</td><td/></tr><tr><td>379299</td><td>rimexolone Ophthalmic Suspension</td><td/></tr><tr><td>1157440</td><td>rimexolone Ophthalmic Product</td><td/></tr><tr><td>1188083</td><td>Vexol Ophthalmic Product</td><td/></tr></table></li></ul></div>
  </text>
  <url value="http://hl7.org/fhir/uv/pddi/ValueSet/valueset-rimexolone-exclude"/>
  <version value="0.1.0"/>
  <name value="valueset-rimexolone-exclude"/>
  <title value="Exclude Rimexolone Medications Value Set"/>
  <status value="draft"/>
  <date value="2018-07-02"/>
  <publisher value="PDDI CDS"/>
  <contact>
    <name value="Richard Boyce boycerd@upmc.edu"/>
  </contact>
  <description
               value="ValueSet containing drug identifiers to exclude. Criteria is explicitly stating topical, gel, cream, ointment, otic, or ophthalmic formulations."/>
  <jurisdiction>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <code value="International"/>
    </coding>
  </jurisdiction>
  <purpose value="To refine valueset for Warfarin + NSAID PDDI-CDS"/>
  <copyright value="Attribution CC BY"/>
  <compose>
    <include>
      <system value="http://www.nlm.nih.gov/research/umls/rxnorm"/>
      <version value="02-Jul-2018"/>
      <concept>
        <code value="207446"/>
        <display value="rimexolone 10 MG/ML Ophthalmic Suspension [Vexol]"/>
      </concept>
      <concept>
        <code value="365826"/>
        <display value="rimexolone Ophthalmic Suspension [Vexol]"/>
      </concept>
      <concept>
        <code value="199115"/>
        <display value="rimexolone 10 MG/ML Ophthalmic Suspension"/>
      </concept>
      <concept>
        <code value="379299"/>
        <display value="rimexolone Ophthalmic Suspension"/>
      </concept>
      <concept>
        <code value="1157440"/>
        <display value="rimexolone Ophthalmic Product"/>
      </concept>
      <concept>
        <code value="1188083"/>
        <display value="Vexol Ophthalmic Product"/>
      </concept>
    </include>
  </compose>
</ValueSet>